

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO-1449A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

## Complete if Known

Application Number	10/618,578
Filing Date	07/11/2003
First Named Inventor	Eigenbrodt et al.
Group Art Unit	4614-1626
Examiner Name	unassigned E. Sackey

Attorney Docket Number SCHE/US/0302

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office <sup>3</sup>	Number <sup>4</sup>	Class/Subclass			
ES	1	DE	198 57009 A1	A61K 31/44	Lindner et al.	06-15-2000	
ES	2	WO	99/54286	C07C 255/00	Uckun et al.	10-28-1999	

Examiner  
Signature*Eric Sackey*Date  
Considered*8/21/05*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/618,578
Sheet	2	of	2	Filing Date	07/11/2003
				First Named Inventor	Eigenbrodt et al.
				Group Art Unit	4614 1626
				Examiner Name	unassigned E. Sackey
				Attorney Docket Number	SCHE/US/0302

OTHER PRIOR ART—NON-PATENT LITERATURE DOCUMENTS		
Examiner initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
E.P	A1	EIGENBRODT, E.; GERBRACHT, U; MAZUREK, S.; PRESEK, P.; FRUS, R. "Carbohydrate Metabolism and Neoplasia: New Perspectives for Diagnosis and Therapy". Biochemical and Molecular Aspects of Selected Cancers. Chapter 10. Vol. 2. pp. 311 – 385. 1994
E.S	A2	KAUPPINEN, RISTO A.; SIHRA, TALVINDER S.; NICHOLLS, DAVID G. "Aminooxyacetic acid inhibits the malate-aspartate shuttle in isolated nerve terminals and prevents the mitochondria from utilizing glycolytic substrates". Elsevier Science Publishers (Biomedical Division). Vol. 930. 1987. pp. 173-178.
E.S	A3	TOMASIAK, MARIAN. "The Importance of Aspartate Aminotransferase for Platelet Aggregation". Haematologia. Vol. 19. No. 2. 1986. pp. 101-112.
E.S	A4	TOMASIAK, MARIAN. "Importance of the malate-aspartate shuttle for the reoxidation of glycolytically produced nadh and for cell aggregation in procine blood platelets". Acta Biochemica Polonica. Vol. 34. No. 3. 1987. pp. 269-284.

Examiner Signature	<i>Ken Sackey</i>	Date Considered	<i>8/12/05</i>
--------------------	-------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.